IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

An experimental once-weekly insulin known as efsitora has shown comparable effectiveness to daily insulin regimens in ...

Intermittent fasting seems to be a safe and potentially healthy eating regimen mostly due to its influence on weight loss ...

Researchers found a higher daily intake of red meats, dairy low fat, pizza and other savory snacks were the main culprits.

In a system often short on resources, it is these moments of human intuition and perseverance that define the best of Indian ...

A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide - a ...

Tuesday's instalment of the Channel 5 show saw the young farmer celebrate his 21st birthday with a trip to Whitby.

Metformin use may enhance progression-free survival (PFS) in patients receiving first-line systemic therapy for patients with ...

The printed cells remained alive and functional in test tubes for up to three weeks, maintaining strong insulin responses to glucose and showing real potential for future clinical use, the researchers ...

Type 1 diabetes affects over 8 million people around the world. It’s a lifelong condition that occurs when the immune system ...

Medicaid insures one in four Pennsylvania residents, and it is poised for cuts under President Donald Trump’s first major ...